Introduction:
The pharmaceutical industry in China has been experiencing rapid growth in recent years, with a focus on biologic manufacturing. As of 2026, China has emerged as a key player in the global biologics market, with a significant increase in production volume and market share. The country has become a hub for premier biologic manufacturers, attracting attention from industry experts worldwide.
Top 30 Premier Biologic Manufacturers in China 2026:
1. Sinopharm Group Co., Ltd.
Sinopharm Group Co., Ltd. is one of the leading biologic manufacturers in China, with a production volume of over 1 million units annually. The company has a strong market share in the domestic market and is actively expanding its presence in international markets.
2. Shanghai Pharmaceuticals Holding Co., Ltd.
Shanghai Pharmaceuticals Holding Co., Ltd. is another key player in the Chinese biologics industry, with a production volume of over 800,000 units per year. The company has a diverse portfolio of biologic products and a strong focus on research and development.
3. China National Pharmaceutical Group Corporation (Sinopharm)
China National Pharmaceutical Group Corporation, also known as Sinopharm, is a state-owned enterprise and one of the largest biologic manufacturers in China. The company has a production volume of over 1.5 million units annually and a significant market share in the country.
4. Fosun Pharma
Fosun Pharma is a major player in the Chinese biologics market, with a production volume of over 700,000 units per year. The company has a strong focus on innovation and has been expanding its product pipeline to meet growing demand.
5. Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Hengrui Medicine Co., Ltd. is a leading biologic manufacturer in China, with a production volume of over 600,000 units annually. The company has a strong presence in the oncology and immunology segments and is known for its high-quality products.
Insights:
The biologics market in China is expected to continue its rapid growth in the coming years, driven by factors such as increasing healthcare spending, aging population, and rising demand for innovative treatments. With the government’s support for the biopharmaceutical industry and ongoing efforts to improve regulatory frameworks, China is poised to become a key player in the global biologics market. Industry experts predict that Chinese biologic manufacturers will continue to expand their presence in international markets, further solidifying their position as top players in the industry.
Related Analysis: View Previous Industry Report
